GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 6

Exenatide Continued to Reduce Weight in 3-Year Completers (n=217) Exenatide produced progressive weight loss over a 3-year period.   Buse J, Macconell L, Stonehouse A, et al. Exenatide maintained glycemic control with associated weight reduction over three years in patients with type 2 diabetes. Presented at: ADA 67th Scientific Sessions; June 22-26, 2007; Chicago, IL. Abstract 0283-OR.

GLP-1 and Central Nervous System Induces the differentiation of neuronal cells in culture, similar to nerve growth factor Protects against neuronal death, via a mechanism involving increased cAMP Protects against beta-amyloid–induced neurotoxicity (Alzheimer’s disease) and suppresses neurodegenerative cascades GLP-1 analogues may have a role in the prevention of neurodegenerative disorders.

Actions of DPP-4 Inhibitors and GLP-1R Agonists in Regulating Glucose Homeostasis Differences between the effect of DPP-4 inhibitors and GLP-1 receptor agonists (exenatide) are related to differences in the plasma GLP-1 levels achieved with the two therapies. DPP-4 inhibitors cause a physiologic rise in the plasma GLP-1 concentration (to 10-15 pmol/L), whereas exenatide causes a pharmacologic rise in the plasma GLP-1 concentration (50-60 pmol/L). Satiety, weight loss, and delayed gastric emptying only are observed with pharmacologic levels of GLP-1, ie, as seen with exenatide.

Summary of Pharmacologic Incretin Actions on Different Target Tissues Heart Brain Neuroprotection Stomach Appetite Gastric Emptying Cardioprotection Cardiac Output GLP-1 _ Liver Same as slide #4 – emphasize cardiac aspects. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):154-165. GI Tract Insulin Secretion β-Cell Neogenesis β-Cell Apoptosis Glucagon Secretion Glucose Production + Glucose Uptake Muscle Drucker DJ, Cell Metab. 2006;3:153-165.

Cardiac Actions of GLP-1 ↑ Cardiac output, ↓ LV end diastolic pressure, and ↑ myocardial glucose uptake in animal (rodent and dog) models of CHF and myocardial injury ↓ Infarct size in ischemic animal models ↑ LVEF and ↑ wall motion in humans with MI and EF <40% GLP-1 (9-36)amide ↑ myocardial contractility (dp/dt) and glucose uptake in dogs with cardiomyopathy GLP-1 and its metabolites may have clinically important effects to enhance cardiac performance.

Emerging Roles of Bioactive GLP-1 Metabolites GLP-1 (7-36) amide and GIP (1-42) amide (left) and the metabolites of GLP-1 (9-36) amide (right) have multiple and diverse metabolic and cardiovascular effects. By blocking the generation of some of the metabolites of GLP-1 (7-36) amide, DPP-4 inhibitors may reduce the effectiveness of endogenously secreted GLP-1 on some metabolic/cardiovascular pathways. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007;30(6)1335-1343.

DPP-4 Degrades Multiple Peptide Substrates DPP-4 degrades multiple peptides in the human body. The long-term effect(s) of inhibition of the degradation of these peptides remains to be determined.   Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007;30(6)1335-1343.

GLP-1R Agonists vs DPP-4 Inhibitors Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.

Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47(2):159-169. GLP-1 vs DPP-4 Inhibitors: Understanding the Antidiabetic Actions of Incretin-Based Therapies This slide highlights areas of similarity among GLP-1 receptor agonists and DPP-4 inhibitors (both enhance glucose-dependent insulin secretion and decrease inappropriate glucagon secretion), as well as areas of difference (only GLP-1 agonists slow gastric emptying, and act centrally to promote satiety and decrease feeding). Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-520. Larsson H, Holst JJ, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand. 1997;160(4):413-422. Nauck MA, Wollschläger D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39(12):1546-1553. Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47(2):159-169.